RECRUITING

MAnnitol for Blood Pressure Stability in HemoDialysis (MAP-HD)

Description

This proposal will measure the effects of mannitol administration versus placebo in hypotensive-prone, adult, maintenance hemodialysis patients with respect to changes in patient symptoms and blood pressure stability.

Conditions

Hemodialysis ComplicationHemodynamic Instability
Talk to us

Related Conditions:

Hemodialysis ComplicationHemodynamic Instability

Study Overview

On this page

Study Details

Study overview

This proposal will measure the effects of mannitol administration versus placebo in hypotensive-prone, adult, maintenance hemodialysis patients with respect to changes in patient symptoms and blood pressure stability.

MAnnitol for Blood Pressure Stability in HemoDialysis (MAP-HD)

MAnnitol for Blood Pressure Stability in HemoDialysis (MAP-HD)

Condition
Hemodialysis Complication
Intervention / Treatment

-

Contacts and Locations

Boston

Brigham and Women's, Boston, Massachusetts, United States, 02115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Maintenance HD (\>90 days)
  • * Age ≥18y
  • * Thrice-weekly HD
  • * IDH-prone (defined as nadir intra-dialytic SBP \<100 mmHg in ≥30% of sessions in the prior 4 weeks)
  • * Hematocrit\>21%
  • * Written informed consent
  • * Acute myocardial infarction or stroke within one month
  • * Pre-HD serum potassium \>6.5 mmol/L in last 4 weeks
  • * Pregnancy
  • * Institutionalized individuals
  • * Life expectancy \<2 months
  • * Planned renal transplant within 2 months
  • * Active enrollment in another interventional trial
  • * Known allergy to mannitol

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Brigham and Women's Hospital,

Finnian R Mc Causland, MBBCH, MMSc, PRINCIPAL_INVESTIGATOR, Brigham and Women's Hospital

Study Record Dates

2024-12-31